Literature DB >> 24092334

Definition and classification of pulmonary hypertension.

Marc Humbert1, David Montani, Oleg V Evgenov, Gérald Simonneau.   

Abstract

Pulmonary hypertension is defined as an increase of mean pulmonary arterial pressure ≥25 mmHg at rest as assessed by right heart catheterization. According to different combinations of values of pulmonary wedge pressure, pulmonary vascular resistance and cardiac output, a hemodynamic classification of pulmonary hypertension has been proposed. Of major importance is the pulmonary wedge pressure which allows to distinguish pre-capillary (pulmonary wedge pressure ≤15 mmHg) and post-capillary (pulmonary wedge pressure >15 mmHg) pulmonary hypertension. Pre-capillary pulmonary hypertension includes the clinical groups 1 (pulmonary arterial hypertension), 3 (pulmonary hypertension due to lung diseases and/or hypoxia), 4 (chronic thrombo-embolic pulmonary hypertension) and 5 (pulmonary hypertension with unclear and/or multifactorial mechanisms). Post-capillary pulmonary hypertension corresponds to the clinical group 2 (pulmonary hypertension due to left heart diseases).

Entities:  

Mesh:

Year:  2013        PMID: 24092334     DOI: 10.1007/978-3-642-38664-0_1

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  9 in total

Review 1.  The Impact of ACE and ACE2 Gene Polymorphisms in Pulmonary Diseases Including COVID-19.

Authors:  Iphigenia Gintoni; Maria Adamopoulou; Christos Yapijakis
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

Review 2.  Molecular Insight into the Therapeutic Effects of Stem Cell-Derived Exosomes in Respiratory Diseases and the Potential for Pulmonary Delivery.

Authors:  Mohammad H Azhdari; Nima Goodarzi; Mohammad Doroudian; Ronan MacLoughlin
Journal:  Int J Mol Sci       Date:  2022-06-03       Impact factor: 6.208

Review 3.  Modulation of miRNAs in Pulmonary Hypertension.

Authors:  Sudhiranjan Gupta; Li Li
Journal:  Int J Hypertens       Date:  2015-03-11       Impact factor: 2.420

4.  Aldehyde dehydrogenase 2 protects against oxidative stress associated with pulmonary arterial hypertension.

Authors:  Tao Xu; Shuangyue Liu; Tingting Ma; Ziyi Jia; Zhifei Zhang; Aimei Wang
Journal:  Redox Biol       Date:  2016-12-21       Impact factor: 11.799

Review 5.  Systems biology: An emerging strategy for discovering novel pathogenetic mechanisms that promote cardiovascular disease.

Authors:  Bradley A Maron; Jane A Leopold
Journal:  Glob Cardiol Sci Pract       Date:  2016-09-30

6.  Hypoxia induces pulmonary arterial fibroblast proliferation, migration, differentiation and vascular remodeling via the PI3K/Akt/p70S6K signaling pathway.

Authors:  Xiaoyu Chai; Dan Sun; Qian Han; Liang Yi; Yanping Wu; Xinmin Liu
Journal:  Int J Mol Med       Date:  2018-02-06       Impact factor: 4.101

Review 7.  Identifying Patients with Pulmonary Arterial Hypertension Using Administrative Claims Algorithms.

Authors:  Stephen C Mathai; Anna Ryan Hemnes; Scott Manaker; Rebekah H Anguiano; Bonnie B Dean; Vishal Saundankar; Peter Classi; Andrew C Nelsen; Kathryn Gordon; Corey E Ventetuolo
Journal:  Ann Am Thorac Soc       Date:  2019-07

Review 8.  Noncoding RNAs in Hypertension.

Authors:  Amela Jusic; Yvan Devaux
Journal:  Hypertension       Date:  2019-07-29       Impact factor: 10.190

Review 9.  Novel Therapeutic Targets for Hypoxia-Related Cardiovascular Diseases: The Role of HIF-1.

Authors:  Minxuan Liu; Gina Galli; Yilin Wang; Qiru Fan; Zhenzhong Wang; Xin Wang; Wei Xiao
Journal:  Front Physiol       Date:  2020-07-15       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.